메뉴 건너뛰기




Volumn 28, Issue 4, 2014, Pages 387-394

Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program

Author keywords

antipsychotics; asenapine; early improvement predictor of treatment outcome; remission; response; Schizophrenia

Indexed keywords

ASENAPINE; HALOPERIDOL; OLANZAPINE; PLACEBO; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; NEUROLEPTIC AGENT;

EID: 84896756353     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113517956     Document Type: Article
Times cited : (30)

References (42)
  • 1
    • 0345167930 scopus 로고    scopus 로고
    • Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected
    • Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry. 2003 ; 60: 1228-1235
    • (2003) Arch Gen Psychiatry , vol.60 , pp. 1228-1235
    • Agid, O.1    Kapur, S.2    Arenovich, T.3
  • 2
    • 46249123414 scopus 로고    scopus 로고
    • Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders
    • Agid O, Kapur S, Warrington L, et al. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res. 2008 ; 102: 241-248
    • (2008) Schizophr Res , vol.102 , pp. 241-248
    • Agid, O.1    Kapur, S.2    Warrington, L.3
  • 3
    • 84864348832 scopus 로고    scopus 로고
    • Placebo-related effects in clinical trials in schizophrenia: What is driving this phenomenon and what can be done to minimize it?
    • Alphs L, Benedetti F, Fleischhacker WW, et al. Placebo-related effects in clinical trials in schizophrenia: What is driving this phenomenon and what can be done to minimize it?. Int J Neuropsychopharmacol. 2012 ; 15: 1003-1014
    • (2012) Int J Neuropsychopharmacol , vol.15 , pp. 1003-1014
    • Alphs, L.1    Benedetti, F.2    Fleischhacker, W.W.3
  • 4
    • 84870469320 scopus 로고    scopus 로고
    • 4th edn. text revision (DSM-IV-TR). Washington, DC; American Psychiatric Publishing Inc.
    • Diagnostic and Statistical Manual of Mental Disorders. 2000 ) Diagnostic and Statistical Manual of Mental Disorders. 4th edn. text revision (DSM-IV-TR). Washington, DC; American Psychiatric Publishing Inc. Washington, DC: American Psychiatric Publishing Inc ; 2000 :
    • (2000) Diagnostic and Statistical Manual of Mental Disorders
  • 5
    • 14844334624 scopus 로고    scopus 로고
    • Remission in schizophrenia: Proposed criteria and rationale for consensus
    • Andreasen NC, Carpenter WT, Kane JM, et al. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry. 2005 ; 162: 441-449
    • (2005) Am J Psychiatry , vol.162 , pp. 441-449
    • Andreasen, N.C.1    Carpenter, W.T.2    Kane, J.M.3
  • 6
    • 54249144638 scopus 로고    scopus 로고
    • Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia
    • Ascher-Svanum H, Nyhuis AW, et al. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. Schizophr Bull. 2008 ; 34: 1163-1171
    • (2008) Schizophr Bull , vol.34 , pp. 1163-1171
    • Ascher-Svanum, H.1    Nyhuis, A.W.2
  • 7
    • 0023630984 scopus 로고
    • Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement
    • Bartkó G, Herczeg I, Békésy M. Predicting outcome of neuroleptic treatment on the basis of subjective response and early clinical improvement. J Clin Psychiatry. 1987 ; 48: 363-365
    • (1987) J Clin Psychiatry , vol.48 , pp. 363-365
    • Bartkó, G.1    Herczeg, I.2    Békésy, M.3
  • 8
    • 33751116815 scopus 로고    scopus 로고
    • Optimizing early prediction for antipsychotic response in schizophrenia
    • Chang YC, Lane HY, Yang KH, et al. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol. 2006 ; 26: 554-559
    • (2006) J Clin Psychopharmacol , vol.26 , pp. 554-559
    • Chang, Y.C.1    Lane, H.Y.2    Yang, K.H.3
  • 9
    • 1842435000 scopus 로고    scopus 로고
    • Early prediction of antipsychotic response in schizophrenia
    • Correll CU, Malhotra AK, Kaushik S, et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003 ; 160: 2063-2065
    • (2003) Am J Psychiatry , vol.160 , pp. 2063-2065
    • Correll, C.U.1    Malhotra, A.K.2    Kaushik, S.3
  • 10
    • 33644698983 scopus 로고    scopus 로고
    • World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia
    • Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: Acute treatment of schizophrenia. World J Biol Psychiatry. 2005 ; 6: 132-191
    • (2005) World J Biol Psychiatry , vol.6 , pp. 132-191
    • Falkai, P.1    Wobrock, T.2    Lieberman, J.3
  • 12
    • 79955474605 scopus 로고    scopus 로고
    • Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia
    • Hatta K, Otachi T, Sudo Y, et al. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophr Res. 2011 ; 128: 127-135
    • (2011) Schizophr Res , vol.128 , pp. 127-135
    • Hatta, K.1    Otachi, T.2    Sudo, Y.3
  • 13
    • 0033680720 scopus 로고    scopus 로고
    • Selection bias in clinical trials with antipsychotics
    • Hofer A, Hummer M, Huber R, et al. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol. 2000 ; 20: 699-702
    • (2000) J Clin Psychopharmacol , vol.20 , pp. 699-702
    • Hofer, A.1    Hummer, M.2    Huber, R.3
  • 14
    • 70649094031 scopus 로고    scopus 로고
    • Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study
    • Jäger M, Schmauss M, Laux G, et al. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study. Eur Psychiatry. 2009 ; 24: 501-506
    • (2009) Eur Psychiatry , vol.24 , pp. 501-506
    • Jäger, M.1    Schmauss, M.2    Laux, G.3
  • 15
    • 77952154800 scopus 로고    scopus 로고
    • Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia
    • Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010 ; 30: 106-115
    • (2010) J Clin Psychopharmacol , vol.30 , pp. 106-115
    • Kane, J.M.1    Cohen, M.2    Zhao, J.3
  • 16
    • 18744412165 scopus 로고    scopus 로고
    • Evidence for onset of antipsychotic effects within the first 24 hours of treatment
    • Kapur S, Arenovich T, Agid O, et al. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry. 2005 ; 162: 939-946
    • (2005) Am J Psychiatry , vol.162 , pp. 939-946
    • Kapur, S.1    Arenovich, T.2    Agid, O.3
  • 17
    • 0023606101 scopus 로고
    • The positive and negative syndrome scale (PANSS) for schizophrenia
    • Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13: 261-276
    • (1987) Schizophr Bull , vol.13 , pp. 261-276
    • Kay, S.R.1    Fiszbein, A.2    Opler, L.A.3
  • 18
    • 28544441669 scopus 로고    scopus 로고
    • Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: A meta-analysis
    • Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: A meta-analysis. Arch Gen Psychiatry. 2005 ; 62: 1305-1312
    • (2005) Arch Gen Psychiatry , vol.62 , pp. 1305-1312
    • Kemmler, G.1    Hummer, M.2    Widschwendter, C.3
  • 19
    • 46249092841 scopus 로고    scopus 로고
    • Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
    • Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res. 2008 ; 102: 230-240
    • (2008) Schizophr Res , vol.102 , pp. 230-240
    • Kinon, B.J.1    Chen, L.2    Ascher-Svanum, H.3
  • 20
    • 72449167382 scopus 로고    scopus 로고
    • Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia
    • Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology. 2010 ; 35: 581-590
    • (2010) Neuropsychopharmacology , vol.35 , pp. 581-590
    • Kinon, B.J.1    Chen, L.2    Ascher-Svanum, H.3
  • 21
    • 70450260607 scopus 로고    scopus 로고
    • Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride
    • Lambert M, Schimmelmann BG, Naber D, et al. Early- and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry. 2009 ; 42: 277-283
    • (2009) Pharmacopsychiatry , vol.42 , pp. 277-283
    • Lambert, M.1    Schimmelmann, B.G.2    Naber, D.3
  • 22
    • 77957844776 scopus 로고    scopus 로고
    • What's next after 50 years of psychiatric drug development: An FDA perspective
    • Laughren TP. What's next after 50 years of psychiatric drug development: An FDA perspective. J Clin Psychiatry. 2010 ; 71: 1196-1204
    • (2010) J Clin Psychiatry , vol.71 , pp. 1196-1204
    • Laughren, T.P.1
  • 23
    • 62849099049 scopus 로고    scopus 로고
    • How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials
    • Leucht S, Arbter D, Engel RR, et al. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry. 2009a ; 14: 429-447
    • (2009) Mol Psychiatry , vol.14 , pp. 429-447
    • Leucht, S.1    Arbter, D.2    Engel, R.R.3
  • 24
    • 20444369114 scopus 로고    scopus 로고
    • Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended
    • Leucht S, Busch R, Hamann J, et al. Early-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended. Biol Psychiatry. 2005a ; 57: 1543-1549
    • (2005) Biol Psychiatry , vol.57 , pp. 1543-1549
    • Leucht, S.1    Busch, R.2    Hamann, J.3
  • 25
    • 33947729638 scopus 로고    scopus 로고
    • Early prediction of antipsychotic nonresposne among patients with schizophrenia
    • Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresposne among patients with schizophrenia. J Clin Psychiatry. 2007a ; 68: 353-360
    • (2007) J Clin Psychiatry , vol.68 , pp. 353-360
    • Leucht, S.1    Busch, R.2    Kissling, W.3
  • 26
    • 34547876496 scopus 로고    scopus 로고
    • Defining 'response' in antipsychotic drug trials: Recommendations for the use of scale-derived cutoffs
    • Leucht S, Davis JM, Engel RR, et al. Defining 'response' in antipsychotic drug trials: Recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology. 2007b ; 32: 1903-1910
    • (2007) Neuropsychopharmacology , vol.32 , pp. 1903-1910
    • Leucht, S.1    Davis, J.M.2    Engel, R.R.3
  • 27
    • 64349118890 scopus 로고    scopus 로고
    • Definitions of response and remission in schizophrenia: Recommendations for their use and their presentation
    • Leucht S, Davis JM, Engel RR, et al. Definitions of response and remission in schizophrenia: Recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009b ; 438: 7-14
    • (2009) Acta Psychiatr Scand Suppl , vol.438 , pp. 7-14
    • Leucht, S.1    Davis, J.M.2    Engel, R.R.3
  • 28
    • 33748771190 scopus 로고    scopus 로고
    • Linking the PANSS, BPRS, and CGI: Clinical implications
    • Leucht S, Kane JM, Etschel E, et al. Linking the PANSS, BPRS, and CGI: Clinical implications. Neuropsychopharmacology. 2006 ; 31: 2318-2325
    • (2006) Neuropsychopharmacology , vol.31 , pp. 2318-2325
    • Leucht, S.1    Kane, J.M.2    Etschel, E.3
  • 30
    • 42749091544 scopus 로고    scopus 로고
    • Predicting antipsychotic drug response - Replication and extension to six weeks in an international olanzapine study
    • Leucht S, Shamsi SA, Busch R, et al. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study. Schizophr Res. 2008 ; 101: 312-319
    • (2008) Schizophr Res , vol.101 , pp. 312-319
    • Leucht, S.1    Shamsi, S.A.2    Busch, R.3
  • 31
    • 36849032267 scopus 로고    scopus 로고
    • Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI
    • Levine SZ, Rabinowitz J, Engel R, et al. Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI. Schizophr Res. 2008 ; 98: 318-322
    • (2008) Schizophr Res , vol.98 , pp. 318-322
    • Levine, S.Z.1    Rabinowitz, J.2    Engel, R.3
  • 32
    • 35948929805 scopus 로고    scopus 로고
    • Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine
    • Lin CH, Chou LS, Lin CH, et al. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J Clin Psychiatry. 2007 ; 68: 1522-1527
    • (2007) J Clin Psychiatry , vol.68 , pp. 1522-1527
    • Lin, C.H.1    Chou, L.S.2    Lin, C.H.3
  • 33
    • 30044439100 scopus 로고    scopus 로고
    • Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled post-hoc analysis of four atypical antipsychotic drugs
    • Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005 ; 3: 21
    • (2005) BMC Med , vol.3 , pp. 21
    • Liu-Seifert, H.1    Adams, D.H.2    Kinon, B.J.3
  • 34
    • 0021074155 scopus 로고
    • The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients
    • Nedopil N, Pflieger R, Rüther E. The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Pharmacopsychiatria. 1983 ; 16: 201-205
    • (1983) Pharmacopsychiatria , vol.16 , pp. 201-205
    • Nedopil, N.1    Pflieger, R.2    Rüther, E.3
  • 36
    • 35948982974 scopus 로고    scopus 로고
    • Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial
    • Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007 ; 68: 1492-1500
    • (2007) J Clin Psychiatry , vol.68 , pp. 1492-1500
    • Potkin, S.G.1    Cohen, M.2    Panagides, J.3
  • 37
    • 17644371975 scopus 로고    scopus 로고
    • How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?
    • Riedel M, Strassnig M, Müller N, et al. How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?. Eur Arch Psychiatry Clin Neurosci. 2005 ; 255: 143-148
    • (2005) Eur Arch Psychiatry Clin Neurosci , vol.255 , pp. 143-148
    • Riedel, M.1    Strassnig, M.2    Müller, N.3
  • 38
    • 79651470675 scopus 로고    scopus 로고
    • Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
    • Ruberg SJ, Chen L, Stauffer V, et al. Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia. BMC Psychiatry. 2011 ; 11: 23
    • (2011) BMC Psychiatry , vol.11 , pp. 23
    • Ruberg, S.J.1    Chen, L.2    Stauffer, V.3
  • 39
    • 78649388138 scopus 로고    scopus 로고
    • Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study
    • Schennach-Wolff R, Obermeier M, Seemüller F, et al. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic study. J Clin Psychopharmacol. 2010 ; 30: 726-731
    • (2010) J Clin Psychopharmacol , vol.30 , pp. 726-731
    • Schennach-Wolff, R.1    Obermeier, M.2    Seemüller, F.3
  • 40
    • 79953079202 scopus 로고    scopus 로고
    • Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis
    • Stauffer V, Case M, Kinon BJ, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res. 2011 ; 187: 42-48
    • (2011) Psychiatry Res , vol.187 , pp. 42-48
    • Stauffer, V.1    Case, M.2    Kinon, B.J.3
  • 41
    • 0027194208 scopus 로고
    • Early response to haloperidol treatment in chronic schizophrenia
    • Stern RG, Kahn RS, Harvey PD, et al. Early response to haloperidol treatment in chronic schizophrenia. Schizophr Res. 1993 ; 10: 165-171
    • (1993) Schizophr Res , vol.10 , pp. 165-171
    • Stern, R.G.1    Kahn, R.S.2    Harvey, P.D.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.